← Baroda BNP Paribas Mutual Fund

Baroda BNP Paribas Health and Wellness Fund Direct Growth

Equity Data as of May 2026 Comparing Apr 2026 → May 2026
Share: WhatsApp X
Stocks Held
33
May 2026
Equity Holdings
₹530.09 Cr
Equity only, excl. debt & cash
Top 5 Weight
31.4%
Moderate
Top 10 Weight
54.0%
Moderate
Changes
35
1 new · 3 exits
Top Sector
Pharmaceuticals & Biotechnology
68.5% of portfolio
📋 What Happened This Month Baroda BNP Paribas Health and Wellness Fund Direct Growth made 1 new addition and exited 3 stocks this month. The biggest new buy was Zydus Lifesciences Limited (Pharmaceuticals & Biotechnology) at 1.98% weight. Jupiter Life Line Hospitals Ltd was the biggest exit (Healthcare Services), which was held at 1.04%. Among existing holdings, Divi's Laboratories Limited saw the biggest increase — now at 3.68% of the portfolio. Gland Pharma Limited was trimmed the most, now at 0.41%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 68.5%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Mar 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 64.9% 67.8% +2.9%
Healthcare Services 20.4% 17.9% -2.5%
Insurance 6.3% 7.3% +1.0%
Retailing 1.6% 1.6% +0.0%
IT - Services 1.3% 1.6% +0.3%
Healthcare Equipment & Supplies 1.4% 1.1% -0.3%
Apr 2026 May 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 67.8% 68.5% +0.7%
Healthcare Services 17.9% 17.5% -0.4%
Insurance 7.3% 7.3% 0.0%
Retailing 1.6% 1.7% +0.0%
IT - Services 1.6% 1.5% 0.0%
Healthcare Equipment & Supplies 1.1% 1.0% -0.1%
🟢
Biggest New Buy
Zydus Lifesciences Limited
1.98% weight · Pharmaceuticals & Biotechnology
🔴
Biggest Exit
Jupiter Life Line Hospitals Ltd
1.04% was held · Healthcare Services
Biggest Add
Divi's Laboratories Limited
+1.61% · now 3.68%
Biggest Trim
Gland Pharma Limited
-1.68% · now 0.41%
🤝 Other funds also bought this month
Zydus Lifesciences Limited 23 funds
Zydus Lifesciences Limited
LIC MF Healthcare Fund-Direct Plan-Growth
Bandhan Healthcare Fund - Direct Plan - Growth
HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan + more
👋 Other funds also exited
Cohance Lifesciences Limited 7 funds
Cohance Lifesciences Limited
DSP Large Cap Fund - Direct Plan - Growth
Bandhan Healthcare Fund - Direct Plan - Growth
ICICI Prudential Value Fund (erstwhile Value Discovery Fund) - Direct Plan - Growth + more
Rainbow Childrens Medicare Limited 4 funds
Rainbow Childrens Medicare Limited
BAJAJ FINSERV HEALTHCARE FUND - DIRECT - GROWTH
Baroda BNP Paribas MULTI CAP FUND - Direct Plan - Growth Option
Axis Flexi Cap Fund - Direct Plan - Growth + more
Jupiter Life Line Hospitals Ltd 2 funds
Jupiter Life Line Hospitals Ltd
Baroda BNP Paribas Large and Mid Cap Fund- Direct Plan -Growth Option
Baroda BNP Paribas Balanced Advantage Fund-Direct Plan-Growth Option

What Changed in the Portfolio This Month?

Comparing Apr 2026 → May 2026

Apr 2026 May 2026
🟢 1 New Entry 🔴 3 Exits ↑ 16 Increased ↓ 15 Decreased
#StockSectorWeight (May 2026)
1
Zydus Lifesciences Limited
₹10.78 Cr
Pharmaceuticals & Biotechnology 1.98%
#StockSectorLast Weight (Apr 2026)
1
Jupiter Life Line Hospitals Ltd
₹5.52 Cr
Healthcare Services 1.04%
2
Cohance Lifesciences Limited
₹5.10 Cr
Pharmaceuticals & Biotechnology 0.96%
3
Rainbow Childrens Medicare Limited
₹7.40 L
Healthcare Services 0.01%
#StockSectorApr 2026May 2026Change
1
Divi's Laboratories Limited
₹20.00 Cr
Pharmaceuticals & Biotechnology 2.07% 3.68% +1.61%
2
Laurus Labs Limited
₹31.33 Cr
Pharmaceuticals & Biotechnology 4.78% 5.76% +0.98%
3
Apollo Hospitals Enterprise Limited
₹25.35 Cr
Healthcare Services 4.32% 4.66% +0.34%
4
Acutaas Chemicals Ltd
₹11.29 Cr
Pharmaceuticals & Biotechnology 1.76% 2.07% +0.31%
5
Aster DM Healthcare Limited
₹17.12 Cr
Healthcare Services 2.97% 3.15% +0.18%
6
Max Financial Services Limited
₹6.65 Cr
Insurance 1.05% 1.22% +0.17%
7
Concord Biotech Limited
₹7.88 Cr
Pharmaceuticals & Biotechnology 1.29% 1.45% +0.16%
8
Metropolis Healthcare Limited
₹6.94 Cr
Healthcare Services 1.12% 1.28% +0.16%
9
Abbott India Limited
₹29.54 Cr
Pharmaceuticals & Biotechnology 5.28% 5.43% +0.15%
10
Nephrocare Health Services Ltd
₹8.98 Cr
Healthcare Services 1.50% 1.65% +0.15%
#StockSectorApr 2026May 2026Change
1
Gland Pharma Limited
₹2.25 Cr
Pharmaceuticals & Biotechnology 2.09% 0.41% -1.68%
2
Mankind Pharma Limited
₹17.82 L
Pharmaceuticals & Biotechnology 1.27% 0.03% -1.24%
3
Sun Pharmaceutical Industries Limited
₹49.48 Cr
Pharmaceuticals & Biotechnology 9.38% 9.09% -0.29%
4
Lupin Limited
₹31.75 Cr
Pharmaceuticals & Biotechnology 6.09% 5.83% -0.26%
5
Ajanta Pharma Limited
₹8.79 Cr
Pharmaceuticals & Biotechnology 1.86% 1.61% -0.25%
6
IPCA Laboratories Limited
₹28.20 Cr
Pharmaceuticals & Biotechnology 5.34% 5.18% -0.16%
7
Poly Medicure Limited
₹5.14 Cr
Healthcare Equipment & Supplies 1.09% 0.95% -0.14%
8
ICICI Prudential Life Insurance Company Limited
₹14.61 Cr
Insurance 2.81% 2.69% -0.12%
9
Glenmark Pharmaceuticals Limited
₹14.22 Cr
Pharmaceuticals & Biotechnology 2.72% 2.61% -0.11%
10
Fortis Healthcare Limited
₹23.21 Cr
Healthcare Services 4.35% 4.27% -0.08%

What Stocks Does This Fund Hold?

33 stocks — May 2026

# Stock Sector Cap Weight & Value
1
₹49.48 Cr
Pharmaceuticals & Biotechnology
9.09%
2
₹31.75 Cr
Pharmaceuticals & Biotechnology
5.83%
3
₹31.33 Cr
Pharmaceuticals & Biotechnology
5.76%
4
₹29.54 Cr
Pharmaceuticals & Biotechnology
5.43%
5
₹28.67 Cr
Pharmaceuticals & Biotechnology
5.27%
6
₹28.20 Cr
Pharmaceuticals & Biotechnology
5.18%
7
₹25.35 Cr
Healthcare Services
4.66%
8
₹23.84 Cr
Pharmaceuticals & Biotechnology
4.38%
9
₹23.21 Cr
Healthcare Services
4.27%
10
₹22.44 Cr
Pharmaceuticals & Biotechnology
4.12%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Baroda BNP Paribas Mutual Fund — Portfolio & Holdings
See all funds managed by Baroda BNP Paribas Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.